{
    "organizations": [],
    "uuid": "d1aa30f50dfcaa3af78fa84927650f28af07e8dd",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sellas-life-sciences-announces-pos/brief-sellas-life-sciences-announces-positive-interim-data-from-phase-2b-neuvax-clinical-trial-in-combination-with-herceptin-idUSASC09UGP",
    "ord_in_thread": 0,
    "title": "BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2, 2018 / 12:54 PM / in 7 minutes BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin Reuters Staff 1 Min Read \nApril 2 (Reuters) - Sellas Life Sciences Group Inc: \n* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS \n* CLINICALLY AND STATISTICALLY SIGNIFICANT EFFICACY IN TRIPLE NEGATIVE BREAST CANCER \n* CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN TWO ARMS IN COHORT OF PATIENTS​ \n* ‍ADDITION OF NEUVAX TO HERCEPTIN DID NOT RESULT IN ANY ADDITIONAL CARDIOTOXICITY COMPARED TO HERCEPTIN ALONE​ * TOLERATED​ \n* SPECIFIED INTERIM ANALYSIS SHOWED AN ADVERSE EVENT PROFILE WITH NO NOTABLE DIFFERENCES BETWEEN TREATMENT ARMS​ \n* ‍DSMB RECOMMENDED TO SEEK REGULATORY GUIDANCE BY FDA FOR FURTHER DEVELOPMENT OF COMBINATION OF NEUVAX + HERCEPTIN IN TNBC​ Source text for Eikon: Further company coverage:",
    "published": "2018-04-02T15:51:00.000+03:00",
    "crawled": "2018-04-02T16:04:07.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "minute",
        "life",
        "science",
        "announces",
        "positive",
        "interim",
        "data",
        "phase",
        "2b",
        "neuvax",
        "clinical",
        "trial",
        "combination",
        "herceptin",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "sellas",
        "life",
        "science",
        "group",
        "inc",
        "sellas",
        "life",
        "science",
        "announces",
        "positive",
        "interim",
        "data",
        "phase",
        "2b",
        "clinical",
        "trial",
        "combination",
        "her2",
        "breast",
        "cancer",
        "patient",
        "clinically",
        "statistically",
        "significant",
        "efficacy",
        "triple",
        "negative",
        "breast",
        "cancer",
        "clinically",
        "meaningful",
        "statistically",
        "significant",
        "difference",
        "found",
        "two",
        "arm",
        "cohort",
        "neuvax",
        "herceptin",
        "result",
        "additional",
        "cardiotoxicity",
        "compared",
        "herceptin",
        "specified",
        "interim",
        "analysis",
        "showed",
        "adverse",
        "event",
        "profile",
        "notable",
        "difference",
        "treatment",
        "recommended",
        "seek",
        "regulatory",
        "guidance",
        "fda",
        "development",
        "combination",
        "neuvax",
        "herceptin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}